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Urinary bone resorption marker, deoxypyridinoline (DPD), and serum bone formation marker, bone alkaline phosphatase (BAP), were determined in three cases of osteoporotic patients with alendronate therapy. DPD decreased significantly at 1 month after start of treatment in two cases, and at 2 months in the other case. BAP gradually decreased by 30-40% at 3 months in all cases. The result shows that the determination of bone markers is useful for drug selection and early assessment of treatment efficacy in osteoporosis.